Yale University, CT.
Dr Pusztai is Professor of Medicine at Yale University, Director of Breast Cancer Translational Research and Co-Director of the Yale Cancer Center Genomics Genetics and Epigenetics Program. He is also Chair of the Breast Cancer Research Committee of the Southwest Oncology Group (SWOG). He received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. He made important contributions to clarify the clinical value of preoperative (neoadjuvant) chemotherapy in different breast cancer subtypes and more recently made important contributions to clarify the role of immunotherapy in breast cancer. Dr Pusztai is principal investigator of several clinical trials investigating the role of immunotherapies and ctDNA monitoring in breast cancer. He has published over 300 scientific manuscripts in high impact medical journals including the NEJM, JAMA, Journal of Clinical Oncology, Nature Biotechnology, PNAS, Lancet Oncology and JNCI. He is among the top 1% most highly cited investigators in clinical medicine according to a 2015 Thomson Reuters report. He is member of the Scientific Advisory Board of the Breast Cancer Research Foundation and a Susan Komen Scholar.